As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...
In patients with proliferative diabetic retinopathy, treatment with anti–vascular endothelial growth factor (anti-VEGF) may offer a safer alternative to panretinal photocoagulation (PRP), leading to ...
Please provide your email address to receive an email when new articles are posted on . From 2017 to 2022, aflibercept was the most commonly used anti-VEGF agent in all U.S. Census regions.
STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results